Tumorad is under clinical development by Spago Nanomedical and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tumorad’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tumorad overview

Tumorad is under development for the treatment of solid tumors, colorectal cancer andtriple-negative breast cancer (TNBC) and metastatic castration-resistant prostate cancer (mCRPC). The drug candidate is administered through intravenous route. The drug candidate consists of organophosphilane hydrogel, loaded with radioactive isotopes/radionuclides. It is developed based on IonXgel nanomaterial technology.

Spago Nanomedical overview

Spago Nanomedical is a research and development company that develops nanomedical products for the diagnosis and treatment of cancer. It offers spagopix, a magnetic resonance imaging contrast agent to improve the visualization of soft tissue tumors and metastases, and tumorad, a nanomedical therapeutic agent loaded with radioactive isotopes in order to enable internal tumor selective radiotherapy. Spago portfolio include pipeline, Spagopix, tumorad. It uses its internally developed technologies as therapeutics, diagnostics, theranostics and drug delivery agents. The company caters to pharmaceutical industry for discovery research, early clinical application and business development. Spago Nanomedical is headquartered in Lund city, Lund, Sweden.

For a complete picture of Tumorad’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.